Institution
American Cancer Society
Nonprofit•Atlanta, Georgia, United States•
About: American Cancer Society is a nonprofit organization based out in Atlanta, Georgia, United States. It is known for research contribution in the topics: Cancer & Population. The organization has 1339 authors who have published 3700 publications receiving 688166 citations. The organization is also known as: American Cancer Society, ACS & American Society for the Control of Cancer.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The authors examine the relationship between exposure to asbestos dust cigarette smoking and mortality in asbestos workers in the United States and Canada from the records of the International Association of Heat and Frost Insulators and Asbestos Workers.
Abstract: The authors examine the relationship between exposure to asbestos dust cigarette smoking and mortality. The data covering 17800 asbestos workers in the United States and Canada were compiled from the records of the International Association of Heat and Frost Insulators and Asbestos Workers (ANNOTATION)
539 citations
••
536 citations
••
TL;DR: A meta-analysis to establish and compare the mean weighted effect sizes of the 4 most commonly recommended treatments for CRF—exercise, psychological, combined exercise and psychological, and pharmaceutical—and to identify independent variables associated with treatment effectiveness suggests Exercise and psychological interventions are effective for reducing CRF during and after cancer treatment.
Abstract: Importance Cancer-related fatigue (CRF) remains one of the most prevalent and troublesome adverse events experienced by patients with cancer during and after therapy. Objective To perform a meta-analysis to establish and compare the mean weighted effect sizes (WESs) of the 4 most commonly recommended treatments for CRF—exercise, psychological, combined exercise and psychological, and pharmaceutical—and to identify independent variables associated with treatment effectiveness. Data Sources PubMed, PsycINFO, CINAHL, EMBASE, and the Cochrane Library were searched from the inception of each database to May 31, 2016. Study Selection Randomized clinical trials in adults with cancer were selected. Inclusion criteria consisted of CRF severity as an outcome and testing of exercise, psychological, exercise plus psychological, or pharmaceutical interventions. Data Extraction and Synthesis Studies were independently reviewed by 12 raters in 3 groups using a systematic and blinded process for reconciling disagreement. Effect sizes (Cohen d ) were calculated and inversely weighted by SE. Main Outcomes and Measures Severity of CRF was the primary outcome. Study quality was assessed using a modified 12-item version of the Physiotherapy Evidence-Based Database scale (range, 0-12, with 12 indicating best quality). Results From 17 033 references, 113 unique studies articles (11 525 unique participants; 78% female; mean age, 54 [range, 35-72] years) published from January 1, 1999, through May 31, 2016, had sufficient data. Studies were of good quality (mean Physiotherapy Evidence-Based Database scale score, 8.2; range, 5-12) with no evidence of publication bias. Exercise (WES, 0.30; 95% CI, 0.25-0.36; P P P P = .05). Results also suggest that CRF treatment effectiveness was associated with cancer stage, baseline treatment status, experimental treatment format, experimental treatment delivery mode, psychological mode, type of control condition, use of intention-to-treat analysis, and fatigue measures (WES range, −0.91 to 0.99). Results suggest that the effectiveness of behavioral interventions, specifically exercise and psychological interventions, is not attributable to time, attention, and education, and specific intervention modes may be more effective for treating CRF at different points in the cancer treatment trajectory (WES range, 0.09-0.22). Conclusions and Relevance Exercise and psychological interventions are effective for reducing CRF during and after cancer treatment, and they are significantly better than the available pharmaceutical options. Clinicians should prescribe exercise or psychological interventions as first-line treatments for CRF.
532 citations
••
National Institutes of Health1, Oklahoma State University Center for Health Sciences2, Chinese Academy of Sciences3, University of Milan4, American Cancer Society5, University of Minnesota6, Johns Hopkins University7, University of Washington8, International Agency for Research on Cancer9, University of Toronto10, Fondation Jean Dausset Centre d'Etude du Polymorphisme Humain11, University Health Network12, University of Texas MD Anderson Cancer Center13, Norwegian University of Science and Technology14, University of Tromsø15, French Institute of Health and Medical Research16, University of Tartu17, University of Liverpool18, Fred Hutchinson Cancer Research Center19, deCODE genetics20, University of Cambridge21, University of Göttingen22, German Cancer Research Center23, Ludwig Maximilian University of Munich24
TL;DR: A lung cancer GWAS identified a distinct hereditary contribution to adenocarcinoma, and previously reported association signals on 15q25 and 6p21 were refined, but no additional loci reached genome-wide significance.
Abstract: Three genetic loci for lung cancer risk have been identified by genome-wide association studies (GWAS), but inherited susceptibility to specific histologic types of lung cancer is not well established. We conducted a GWAS of lung cancer and its major histologic types, genotyping 515,922 single-nucleotide polymorphisms (SNPs) in 5739 lung cancer cases and 5848 controls from one population-based case-control study and three cohort studies. Results were combined with summary data from ten additional studies, for a total of 13,300 cases and 19,666 controls of European descent. Four studies also provided histology data for replication, resulting in 3333 adenocarcinomas (AD), 2589 squamous cell carcinomas (SQ), and 1418 small cell carcinomas (SC). In analyses by histology, rs2736100 (TERT), on chromosome 5p15.33, was associated with risk of adenocarcinoma (odds ratio [OR] = 1.23, 95% confidence interval [CI] = 1.13–1.33, p = 3.02 × 10−7), but not with other histologic types (OR = 1.01, p = 0.84 and OR = 1.00, p = 0.93 for SQ and SC, respectively). This finding was confirmed in each replication study and overall meta-analysis (OR = 1.24, 95% CI = 1.17–1.31, p = 3.74 × 10−14 for AD; OR = 0.99, p = 0.69 and OR = 0.97, p = 0.48 for SQ and SC, respectively). Other previously reported association signals on 15q25 and 6p21 were also refined, but no additional loci reached genome-wide significance. In conclusion, a lung cancer GWAS identified a distinct hereditary contribution to adenocarcinoma.
532 citations
National Institutes of Health1, Harvard University2, Mayo Clinic3, New York University4, Utrecht University5, University of Minnesota6, Mercy Medical Center (Baltimore, Maryland)7, American Cancer Society8, Fred Hutchinson Cancer Research Center9, Vanderbilt University10, University of Cambridge11, University of California, San Francisco12, German Cancer Research Center13, French Institute of Health and Medical Research14, Johns Hopkins University15, University of Toronto16, International Agency for Research on Cancer17, Michigan State University18, Veterans Health Administration19, Umeå University20, University of Texas MD Anderson Cancer Center21, Science Applications International Corporation22, Ohio State University23, Memorial Sloan Kettering Cancer Center24, Group Health Cooperative25, Imperial College London26, Aalborg University27, Baylor College of Medicine28, Yale University29, National and Kapodistrian University of Athens30, Kaiser Permanente31, National Institute for Health and Welfare32, University at Buffalo33
TL;DR: An association between a locus on 9q34 and pancreatic cancer marked by the SNP rs505922 is identified, consistent with earlier epidemiologic evidence suggesting that people with blood group O may have a lower risk of pancreaticcancer than those with groups A or B.
Abstract: We conducted a two-stage genome-wide association study of pancreatic cancer, a cancer with one of the lowest survival rates worldwide. We genotyped 558,542 SNPs in 1,896 individuals with pancreatic cancer and 1,939 controls drawn from 12 prospective cohorts plus one hospital-based case-control study. We conducted a combined analysis of these groups plus an additional 2,457 affected individuals and 2,654 controls from eight case-control studies, adjusting for study, sex, ancestry and five principal components. We identified an association between a locus on 9q34 and pancreatic cancer marked by the SNP rs505922 (combined P = 5.37 x 10(-8); multiplicative per-allele odds ratio 1.20; 95% confidence interval 1.12-1.28). This SNP maps to the first intron of the ABO blood group gene. Our results are consistent with earlier epidemiologic evidence suggesting that people with blood group O may have a lower risk of pancreatic cancer than those with groups A or B.
532 citations
Authors
Showing all 1345 results
Name | H-index | Papers | Citations |
---|---|---|---|
Walter C. Willett | 334 | 2399 | 413322 |
Meir J. Stampfer | 277 | 1414 | 283776 |
Frank B. Hu | 250 | 1675 | 253464 |
David J. Hunter | 213 | 1836 | 207050 |
Edward Giovannucci | 206 | 1671 | 179875 |
Irving L. Weissman | 201 | 1141 | 172504 |
Bernard Rosner | 190 | 1162 | 147661 |
Susan E. Hankinson | 151 | 789 | 88297 |
Paolo Boffetta | 148 | 1455 | 93876 |
Jeffrey A. Bluestone | 143 | 515 | 77080 |
Richard D. Smith | 140 | 1180 | 79758 |
Garth D. Illingworth | 137 | 505 | 61793 |
Brian E. Henderson | 137 | 712 | 69921 |
Ahmedin Jemal | 132 | 500 | 380474 |
Michael J. Thun | 129 | 392 | 79051 |